- Home
- QTTB vs NMG Comparison
QTTB vs NMG Comparison
Compare QTTB & NMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QTTB | NMG |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 265.2M | 292.7M |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QTTB | NMG |
|---|---|---|
| Price | $8.75 | $0.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $39.67 | $3.62 |
| AVG Volume (30 Days) | ★ 384.0K | 349.2K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 136.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,737,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.91 | $0.76 |
| 52 Week High | $23.57 | $3.29 |
Technical Indicators
Market Signals| Indicator | QTTB | NMG |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 31.98 |
| Support Level | $8.23 | N/A |
| Resistance Level | $9.25 | $1.04 |
| Average True Range (ATR) | 0.52 | 0.07 |
| MACD | 0.09 | -0.00 |
| Stochastic Oscillator | 34.98 | 15.24 |
Price Performance
Historical ComparisonAbout QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
About NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.